Interacting Drugs |
Ketoconazole (systemic) vs P-glycoprotein/ABCB1 Substrates |
Security Level |
 |
Mechanism |
P-glycoprotein/ABCB1 Substrates: May increase the serum concentration of P-glycoprotein/ABCB1 Inhibitors. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). |
Management |
Monitor therapy |
Ketoconazole (systemic) vs P-glycoprotein/ABCB1 Substrates
Post Review about Ketoconazole (systemic) vs P-glycoprotein/ABCB1 Substrates Click here to cancel reply.
Other Interactions of Ketoconazole (systemic)
Other Interactions of P-glycoprotein/ABCB1 Substrates
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.